2-(N-Allyl-N-methylamino)-4-[2-methyl-5-(2-morpholinopyrid-4-ylcarbonylamino)anilino]pyrimidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(N-Allyl-N-methylamino)-4-[2-methyl-5-(2-morpholinopyrid-4-ylcarbonylamino)anilino]pyrimidine
• 英文别名: N-[4-methyl-3-[[2-[methyl(prop-2-enyl)amino]pyrimidin-4-yl]amino]phenyl]-2-morpholin-4-ylpyridine-4-carboxamide
• 化学式: C₂₅H₂₉N₇O₂
• 分子量: 459.551
• InChiKey: YGWCRRQSSZYPEK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  95.5
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  N-(3-amino-4-methylphenyl)-2-morpholinopyridine-4-carboxamide 在 N,N-二异丙基乙胺 作用下， 以 正丁醇 为溶剂， 生成 2-(N-Allyl-N-methylamino)-4-[2-methyl-5-(2-morpholinopyrid-4-ylcarbonylamino)anilino]pyrimidine
  参考文献：
  名称：

  Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase

  摘要：

  SAR studies led to the identification of 4-(3-benzoylamino-6-methyl-anilino)quinazolines as potent and selective inhibitors of p38 MAP kinase. Further optimisation led to the identification of a series of 4-(3-benzoylamino-6-methyl-anilino)pyr midines as potent inhibitors of the p38 MAP kinase signalling pathway in vitro and in vivo. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.08.007

文献信息

• Pyrimidine derivatives
  申请人：Cumming John Graham

  公开号：US06846827B1

  公开（公告）日：2005-01-25

  The invention concerns pyrimidine derivatives of Formula (I) wherein m is 0-3 and each R 1 is a group such as hydroxy, halogeno, trifluoromethyl and cyano; R 3 is hydrogen, halogeno or (1-6C)alkyl; n is 0-2 and each R 2 is a group such as hydroxy, halogeno, trifluoromethyl and cyano; p is 0-4; and Q 1 is aryl or heteroaryl; or pharmaceutically acceptable salts or in vivo cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.

  本发明涉及式（I）的嘧啶衍生物，其中m为0-3，每个R1是羟基，卤素，三氟甲基和氰基等基团；R3为氢，卤素或（1-6C）烷基；n为0-2，每个R2是羟基，卤素，三氟甲基和氰基等基团；p为0-4；Q1为芳基或杂环芳基；或其药学上可接受的盐或体内可裂解的酯；其制备方法，包含它们的制药组合物以及它们在治疗细胞因子介导的疾病或医学状况中的应用。
• PYRIMIDINE DERIVATIVES
  申请人：AstraZeneca AB

  公开号：EP1226126B1

  公开（公告）日：2005-01-05
• US6846827B1
  申请人：——

  公开号：US6846827B1

  公开（公告）日：2005-01-25
• Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase
  作者：John G. Cumming、Caroline L. McKenzie、Stuart G. Bowden、Douglas Campbell、David J. Masters、Jason Breed、Philip J. Jewsbury

  DOI：10.1016/j.bmcl.2004.08.007

  日期：2004.11

  SAR studies led to the identification of 4-(3-benzoylamino-6-methyl-anilino)quinazolines as potent and selective inhibitors of p38 MAP kinase. Further optimisation led to the identification of a series of 4-(3-benzoylamino-6-methyl-anilino)pyr midines as potent inhibitors of the p38 MAP kinase signalling pathway in vitro and in vivo. (C) 2004 Elsevier Ltd. All rights reserved.